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ABSTRACT 
Introduction: Salivary gland hypofunction is a common and permanent adverse 
effect of radiotherapy to the head and neck. Randomised trials of available treatment 
modalities have produced unclear results and offer little reliable guidance for 
clinicians to inform evidence-based therapy. We have undertaken this systematic 
review and meta-analysis to estimate the effectiveness of available interventions for 
radiotherapy-induced xerostomia and hyposalivation.  
Methods:  We searched MEDLINE, Cochrane Central, EMBASE, AMED, and 
CINAHL database through July 2016 for randomized controlled trials comparing any 
topical or systemic intervention to active and/or non-active controls for the treatment 
of radiotherapy-induced xerostomia. The results of clinically and statistically 
homogenous studies were pooled and meta-analysed.  
Results: 1732 patients from twenty studies were included in the systematic review. 
Interventions included systemic or topical pilocarpine, systemic cevimeline, saliva 
substitutes/mouthcare systems, hyperthermic humidification, acupuncture, 
acupuncture-like transcutaneous electrical nerve stimulation, low-level laser therapy 
and herbal medicine. Results from the meta-analyses, which included six studies, 
suggest that both cevimeline and pilocarpine can reduce xerostomia symptoms and 
increase salivary flow compared to placebo, although some aspects of the relevant 
effect size, duration of the benefit, and clinical meaningfulness remain unclear. With 
regard to interventions not included in the meta-analysis, we found no evidence, or 
very weak evidence, that they can reduce xerostomia symptoms or increase salivary 
flow in this population.  
Conclusions: Pilocarpine and cevimeline should represent the first line of therapy in 
HNC survivors with radiotherapy-induced xerostomia and hyposalivation. The use of 
other treatment modalities cannot be supported on the basis of current evidence.  
Keywords: xerostomia, radiotherapy, acupuncture, sialogogue, saliva  
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INTRODUCTION 
Head and neck cancer (HNC) is the sixth most common cancer worldwide and is 
often managed with radiotherapy, either as monotherapy or in association with 
chemotherapy and surgery [1]. When salivary glands are within the irradiated field, 
irreversible salivary glands damage occurs in 63-93% of the patients [2]. Salivary 
gland damage typically manifests as reduced saliva secretion, which in turn can 
translate into a subjective sensation of dry mouth (xerostomia), oral discomfort, 
altered taste, difficulty with speaking, swallowing, chewing, and increased risk of 
dental disease. Overall hyposalivation and related xerostomia can cause a 
substantial reduction in quality-of-life (QoL) [2]. 
A wide range of interventions for salivary gland hypofunction is available [3]. 
Stimulation of salivary gland function may be appropriate for patients with some 
degree of residual salivary gland parenchyma, and it can be attempted through 
sialogogue medications (such as pilocarpine and cevimeline) [4], or activating the 
salivary reflex arch via chewing gums or sucking pastilles and lozanges [5]. Topical 
application of salivary substitutes can offer some benefit by providing a moisture-
retaining coating onto the oral mucosa [6]. Other interventions, such as acupuncture, 
have also been used to increase saliva production, possibly by enhancing peripheral 
blood flow [7]. However there is currently little robust evidence to inform the 
management of hyposalivation and xerostomia in this population. Some of the 
available systematic reviews have not specifically focused on HNC patients but 
rather considered individuals with xerostomia due to a variety of causes [5]. Others 
focussed on single intervention [8-11], or presented a number of methodological 
weaknesses [12-14]. We have undertaken this multiple-treatment systematic review 
and meta-analysis in order to help estimate the effectiveness of available treatments 
and contribute to develop evidence-based guidelines for the management of 
radiotherapy-induced hyposalivation and xerostomia.  
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METHODS 
We developed a protocol that defined inclusion criteria, search strategy and 
outcomes of interest. The reporting of this systematic review and meta-analysis 
adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement [15]. For the identification of studies to be included in this 
review, we developed detailed search strategies for each database (Medline, 
Embase, The Cochrane Central Register of Controlled Trials, Cinahl, Amed). We 
searched reference lists of retrieved reports for additional references. The last 
literature search was performed on the 07th of July 2016. Study inclusion criteria were 
(i) design: randomized controlled trials; (ii) population: adults with a diagnosis of 
radiotherapy-induced xerostomia; (iii) intervention: techniques designed to stimulate 
saliva production or to replace saliva; (iv) control group: placebo, no intervention, 
another active intervention or a combination of the aforementioned options. The 
interventions could be given by any route, formulation, or dose. No language 
restrictions were imposed. Citations were screened by two independent reviewers 
and full reports of potentially relevant studies were obtained. The methodological 
quality assessment of the selected trials was performed according to the Cochrane 
Collaboration tool for assessing risk of bias [16]. 
The primary subjective outcome measure of this review was the mean overall 
change in xerostomia symptoms, which was assessed by change in a visual 
analogue scale (VAS). Secondary objective outcomes were changes in QoL and 
salivary flow. We looked in detail at the time endpoints used for collection of the 
outcome measures; in particular we considered whether measurements at endpoint 
were taken shortly after the intervention (e.g. few minutes or hours) or away from 
treatment completion (therefore representing xerostomia symptoms and salivary flow 
during resting condition). Further, we considered incidence of adverse effects and 
proportion of patients dropping out as indicators of safety and acceptability. 
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We summarized the effect size for continuous data using the mean difference (MD) 
with 95% confidence intervals (95% CI). For categorical data, we calculated odd ratio 
(OR) of improvement, with 95% CI. Heterogeneity between trials was investigated 
using the I2 index. A fixed effect model was used unless statistical heterogeneity was 
significant (p<0·05), after which a random effect model was used.  
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RESULTS 
Figure 1 shows the process of study selection, leading to the inclusion of 20 studies 
in the systematic review, with a total of 1732 patients. Table 1 shows summary of 
trial characteristics. Table 2 shows study populations, interventions, and extracted 
outcome measures for eligible trials. Seventeen studies used changes in xerostomia 
symptoms as an outcome; outcome measures included the visual analogue scale 
(nine studies) [17-25], the xerostomia inventory (one study) [26], the Walizer Mouth 
Dryness questionnaire (one study) [27], the global rating of change scale (two 
studies in one paper) [28], general xerostomia questionnaires (two studies) [29, 30], 
and the xerostomia items of the European Organization for Research and Treatment 
of Cancer Quality of Life Head and Neck Module (EORTC-H&N35) instrument (two 
studies) [31, 32]. At endpoint, symptoms were assessed shortly after administration 
of the intervention in three studies [28, 29], and after 180 minutes in one trial [19], 
and therefore refer to symptoms perceived by participants during enhancement of 
salivary gland function. Two studies collected xerostomia symptom measurements 
one or more weeks after completion of the experimental treatment [31, 33], therefore 
referring to symptoms perceived by patients during resting salivary condition. Timing 
of measurement collection at endpoint was unclear in twelve studies [17, 18, 20-23, 
25-27, 30, 32, 34]. 
Twelve trials used changes in salivary function assessed through unstimulated 
sialometry as an outcome [17-19, 21, 23, 25, 26, 28, 29, 31, 33, 35]. At endpoint, 
salivary function was assessed shortly after the intervention in four studies [28, 29, 
35], after 60 minutes in two studies [17, 18], and after 180 minutes in one study [19]. 
Two studies assessed salivary flow one or more weeks after completion of the 
experimental treatment [31, 33] whereas the timing of salivary flow collection at 
endpoint remained unclear in three studies [21, 23, 25]. 
Five studies used changes in QoL scores using five different outcome measures 
including the Oral Health Impact Profile [OHIP-49] and University of Washington 
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Quality of Life Questionnaire [UW-QoL] questionnaire in one study [34], and the 
General Oral Health Assessment Index [GOHAI] [26], the EORTC-H&N35 [31], the 
Xerostomia-Related Quality of Life Scale [XeQoL] [33], and the short version of the 
Oral Health Impact Profile [OHIP-14] [23]. Two studies collected QoL measures one 
or more weeks after completion of the intervention [31, 33], whereas timing of 
outcome collection was unclear in three studies [26, 29, 34]. 
Risk of bias  
We considered nine studies (45%) to have a low overall risk of bias (Figure 2). 
Adequate sequence generation and concealment was reported in 75% and 65% of 
studies respectively. Blinding of participants to the allocated treatment by use of a 
placebo was done in 11 of the included studies (55%). Outcome assessors were 
blinded to allocated treatment in 13 trials (65%). Over 90% of the included studies 
reported complete outcome data without selective reporting. 
 
Systematic Review 
Systemic pilocarpine vs placebo.  
Two placebo-controlled trials with low risk of bias reported a reduction in xerostomia 
symptoms after 12-week therapy with systemic pilocarpine [17, 18]. The studies also 
reported a short-term (measured at 60 min) increase in salivation associated with 
use of a single tablet of pilocarpine. The magnitude of improvement was however 
unclear as both studies only reported the number of patients who had an arbitrary 
reduction of at least 25mm in the VAS or any increases in salivation. Clinical 
significance remains unknown. Adverse side effects (sweating, urinary frequency and 
nausea) were seen more frequently in individuals using pilocarpine than in the 
placebo group, with 15-29% of patients in the pilocarpine group withdrawing from the 
study.  
Systemic cevimeline vs placebo.  
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Two research groups assessed the effectiveness of oral cevimeline in three studies 
with low risk of bias [28, 34]. One showed a clinically meaningful improvement in dry 
mouth symptoms in the intervention group, however the magnitude of improvement 
was unclear. The second study failed to show any significant difference between the 
active group and placebo. Both studies reported that 12-week of cevimeline therapy 
is associated with a significant, albeit small, increase in salivation, of possible clinical 
significance. Adverse side effects (sweating and dyspepsia) were seen more 
frequently in individuals using cevimeline, with 13-14% of individuals in the 
cevimeline group withdrawing from the study. A second research group assessed the 
effects of six weeks of cevimeline therapy upon QoL in a study with unclear risk of 
bias due to unclear reporting on allocation concealment; they observed no significant 
differences between experimental and placebo groups [34]. 
Systemic pilocarpine vs “topical” pilocarpine vs topical placebo.   
The topical administration of pilocarpine has been attempted in order to minimize 
absorption and related adverse side effects. Taweechaisupapong et al reported a 
cross-over trial, which they claim was double blinded, where patients received every 
ten days one single pilocarpine tablet to be swallowed, or one pilocarpine lozenge (3 
mg or 5 mg dose) or one placebo lozenge both to be dissolved in the mouth [19]. The 
study reported that the use of one 5mg lozenge was associated with a short-term 
(measured at 180 minutes) reduction in xerostomia and increase in salivary flow in 
significantly more patients than the 3mg lozenge, 5mg pilocarpine tablet and 
placebo. However, the magnitude of improvement was unclear and clinical 
significance unknown. No adverse effects were reported. This study was considered 
at high risk of bias of blinding participants and personnel because, although the 
authors stated it was a double-blind study, the investigators and the patients knew if 
they were receiving the lozenge (to be dissolved) or the tablet (to be swallowed). 
Also, it is rather questionable that dissolving pilocarpine lozenges without spitting the 
content out represents topical treatment.  
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Saliva substitutes vs “topical” pilocarpine.  
One cross-over trial at high risk of bias because of its unblinded design studied the 
effect of three-month use of a spray containing mucin-based artificial saliva (Saliva 
Orthana) compared to a mouthwash containing pilocarpine [20]. The study failed to 
demonstrate statistically significant differences in xerostomia symptom between the 
two groups. Also, it is rather questionable that this was a topical intervention as 
participants were allowed to swallow the medication.  
Mouthcare system vs other mouthcare system.  
Three trials evaluated the effects of “mouthcare systems” containing a combination of 
artificial saliva gel, and/or oral rinse, and/or spray, and/or toothpaste [21, 22, 25]. 
Epstein reported in a high-quality cross-over trial at low risk of bias that patients 
using Biotene gel and toothpaste (enzyme-based and hydroxyethylcellulose-based 
artificial saliva) for two weeks had significantly reduced xerostomia symptom on 
waking (VAS) and increased stimulated salivary flow compared to controls using 
carboxymethylcellulose gel and commercial toothpaste, when data were analysed for 
carryover effect. However the magnitude of the effect and clinical meaningfulness 
was unclear [25]. The same study design was used by Nagy et al who obtained 
similar results [21]. However, the latter study should be considered at high risk of 
bias as, although study measurements refer to the post-radiotherapy period, the 
experimental intervention and placebo treatment were commenced during 
radiotherapy. Shahdad et al studied the effects of two weeks of therapy with two 
enzyme-based salivary substitutes, Oral Balance or BioXtra mouthcare systems (gel, 
mouthwash and toothpaste) in a double-blind cross-over study at low risk of bias 
[22]. Participants using BioXtra treatment, which has higher viscosity and contains 
additional salivary peptides and proteins, achieved a greater improvement in 
xerostomia symptoms compared to those using Oral Balance mouth care system. 
Clinical meaningfulness of the reported improvement is unknown.  
Salivary substitutes vs other salivary substitutes or placebo.  
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Three cross-over trials compared salivary substitutes vs other salivary substitutes or 
placebo [26, 30, 32]. McMillan investigated a novel intra-oral device for the slow 
release of Oral Balance gel versus an oral bolus of the same gel in a four-week 
randomised cross-over study, which did not show any significantly different effect 
upon xerostomia symptoms (Xerostomia Inventory) or salivary flow [26]. However, 
changes in oral health-related quality of life scores (GOHAI) were higher in 
participants using the device. We considered this study as being at high risk of bias 
because of its single-blind design. 
Jellema studied the effects of one-week use of a xanthan gum-based salivary 
substitute (Xialine) versus placebo and found no significant difference upon 
xerostomia symptoms (xerostomia questions of QLQ-H&N35) [32]. Momm tested the 
effects of one-week use of four different salivary substitutes and reported a 
significant reduction in xerostomia symptoms with respect to baseline for all groups 
but not difference among the four groups [30]. We considered the studies of Jellema 
and Momm to be at high risk of bias due to the lack of information on blinding of 
participants and investigators.  
Acupuncture vs sham acupuncture or educational oral care sessions.  
Three controlled trials investigated the therapeutic efficacy of acupuncture in 
radiation-induced xerostomia [29, 31, 35]. The single-blinded study of Cho et al 
reported no statistically significant difference in salivary flow or xerostomia in the 
active group (real acupuncture) versus controls (sham acupuncture) after six weeks 
of twice-a-week treatment [29]. Simcock et al studied the effects of eight weeks of 
once–a-week acupuncture versus educational oral care session (including advice on 
the use of artificial saliva) and reported that those having acupuncture were more 
likely to report an improvement in xerostomia symptoms (as per QLQ-H&N35 and 
other dry mouth questions) compared to controls [31]. Magnitude of the effect, as 
well as clinical significance, was unclear. There were no differences with respect to 
salivary flow or QoL. Finally Blom did not observed any statistical difference in 
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salivary flow between participants randomised to twelve weeks of real or superficial 
acupuncture [35]. We deemed the three studies to have high risk of bias due to the 
overall poor reporting of randomisation and blinding.  
Hyperthermic, supersaturated humidification vs standard bedside humidifier.  
One cross-over study assessed the effectiveness of two-week use of a device 
delivering hyperthermic, supersaturated humidification through a nasal cannula 
compared to a standard bedside humidifier [27]. Dry mouth questionnaires and the 
visual analogue score showed no significant differences between the two devices in 
lessening xerostomia symptoms. This study was considered at unclear risk of bias 
due to unclear sequence generation, allocation concealment, and blinding. 
Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) vs 
pilocarpine.  
One unblinded study investigated the effects of twelve weeks of acupuncture-like 
transcutaneous electrical nerve stimulation (twice-weekly for a total of 24 sessions of 
20 minutes each) versus pilocarpine [33], and found no significant difference in 
Xerostomia-related Quality of Life Scale score or salivary flow between the groups. 
This study was considered at high risk of bias because of lack of details regarding 
sequence generation, allocation concealment and blinding. 
Low-level laser therapy vs sham low-level laser therapy.  
One trial tested the effectiveness of low-level laser therapy in improving xerostomia 
symptoms (VAS), salivary flow and quality of life (assessed through the Oral Health 
Impact Profile questionnaire) [23]. The groups underwent two weekly sessions of 
low-level laser therapy for six weeks but in the control group a plastic tip blocked the 
emission of radiation. The study failed to show any significant difference between the 
groups with regards to long-term changes in xerostomia, salivary flow or QoL score. 
This study was considered at unclear risk of bias due to unclear sequence 
generation, allocation concealment and blinding.  
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Herbal compound vs salivary substitute  
One open-label parallel study assessed the effectiveness of four-week use of an 
herbal compound containing Malva sylvestris and Alcea digitata powder compared to 
artificial saliva (Hypozalix) [24]. No objective measures were used in this study, 
however the visual analogue score showed a significant differences between the two 
treatment in lessening xerostomia symptoms. This study was considered at high risk 
of bias due to selective reporting (75 participants were allocated to the intervention 
but the results are reported only for the 62 completing the trial) and lack of blinding. 
Furthermore only statistical significance is reported in the text and the magnitude of 
benefit can only be approximated by the figure. 
Meta-analysis 
Four trials provided sufficient data to evaluate the primary outcome of the mean 
overall change in xerostomia symptoms. Six studies allowed statistical analysis of the 
assessment of changes in salivary flow rate. It was not possible to analyse the QoL 
outcomes due to differences in the outcome measures among the studies.  
In relation to the primary outcome of reduction in xerostomia symptoms two 
comparisons were sufficiently clinically homogenous to perform statistical pooling: 
systemic pilocarpine vs placebo and systemic cevimeline vs placebo (Figure 3). Two 
studies, with no heterogeneity (I2=6%) among them and a pooled total of 280 
participants showed that the patients using pilocarpine for 12 weeks were more likely 
to have a 25mm or higher reduction in xerostomia VAS score compared to placebo 
(OR of 2·37, 95% CI 1·43-3·94). Two homogeneous studies (I2=0%) with a pooled 
total of 563 participants showed that patients using cevimeline for 12 weeks were 
more likely to report an improvement in the sensation of xerostomia compared to 
placebo (OR 1·37, 95% CI 0·98-1·91).   
In relation to the secondary outcome we were able to compare the effect of 
acupuncture vs sham/superficial acupuncture, cevimeline vs placebo, and 
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pilocarpine vs placebo on unstimulated salivary flow rates (Figure 4 and 5). Two 
studies of acupuncture versus sham/superficial acupuncture with no heterogeneity 
(I2=0%) and a pooled total of 50 participants showed no increase (MD 0·00; 95% CI -
0·02-0·03) in unstimulated/stimulated salivary flow rate. Pooled analysis of two RCTs 
of cevimeline versus placebo (total number of patients = 563) showed a small (MD 
0·04, 95% CI 0·02-0·06) increase in unstimulated saliva flow rate in participants 
using cevimeline for 12 weeks with respect to controls. Two RCTs  (total number of 
patients = 280) showed that the use of one tablet of pilocarpine is more likely to be 
associated with any short-term increase (60 minutes) in unstimulated salivary flow 
rate compared to one tablet of placebo (OR 2·27; 95% CI 1·37-3·76).  
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DISCUSSION 
No clear evidence-based guidance for clinicians is currently available to inform the 
management of radiotherapy-induced hyposalivation and xerostomia in HNC 
survivors. We have previously commented [13] on the questionable validity of the 
systematic review and meta-analysis of Lovelace et al [14] and the systematic review 
performed by Jensen et al [12] also seem to have similar weaknesses such as the 
inclusion of non-randomised studies and linguistic constraints [36, 37]. Other reviews 
focussed on single intervention [8-11]. 
In this multiple-treatment systematic review we have tried to overcome limitations of 
previous studies. Additionally we looked at a number of details of published trials 
(e.g. type of outcome, length of treatment, time of collecting outcome measurement) 
that were not highlighted in previous reviews but we believe are important for the 
interpretation of the efficacy of interventions. We included 20 RCTs with a total of 
1732 randomized patients. Meta-analyses were only possible for three interventions 
because of the limited number of studies and their heterogeneous designs. Where 
data polling was possible, results suggest that long-term use of systemic pilocarpine 
or cevimeline has a positive effect in reducing xerostomia sensation in HNC 
survivors, with likelihood of improvement being higher for pilocarpine. However the 
effect size of such reduction was unclear for pilocarpine (at least 25mm on 0-100mm 
VAS) and not reported for cevimeline. It remains unknown whether a VAS change of 
at least 25mm is clinically relevant in this patient population, whereas the 
improvement in symptoms obtained with cevimeline do seem clinically meaningful 
(as patients reported to feel better/much better). Further, this positive effect seems to 
be limited to symptoms perceived shortly after the administration of the intervention, 
whilst no information is available with respect to dry mouth symptoms perceived 
under resting salivary conditions.  
Pilocarpine and cevimeline also seem effective in increasing salivary flow. Our meta-
analysis shows that long-term use of cevimeline can induce an increase in 
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unstimulated salivation, though the relevant effect size seems small (MD of 0·04 
mL/min). However patients reported to feel better/much better and therefore a MD of 
0·04mL/min may be considered clinical meaningful. With respect to pilocarpine, 
available data only provide evidence of a short-term increase in salivation with the 
use of one tablet (salivary flow measured after 60 minutes), whereas the effect size, 
clinical significance, as well as the effects of long-term use are unknown. Again no 
information is available with respect to salivary gland function under resting 
conditions.  
With respect to acupuncture, data from our meta-analysis show no evidence of 
increased salivary flow and unknown effect upon dry mouth symptoms due to lack of 
data.  
There results have practical implications as clinicians managing HNC survivors with 
post-radiotherapy hyposalivation and dry mouth symptoms should consider 
prescribing long-term cevimeline therapy and expect that it will provide some 
reduction in dry mouth symptoms and a small yet possible clinically meaningful 
increase in salivary flow, although likely to be short-lived. Similarly they should 
expect a reduction in xerostomia symptoms with long-term pilocarpine use, as well 
an increase in salivary flow after one tablet of pilocarpine, although these 
improvements are likely to have a short duration, unclear effect size, and unknown 
clinical significance. The toxicity of pilocarpine and cevimeline seems similar, 
possibly with a tendency for cevimeline to be better tolerated, although evidence is 
not robust as no direct comparison is available.  
With respect to acupuncture, there was no evidence that it increases salivary flow, 
whereas it was not possible to pool data upon changes in dry mouth symptoms. 
Therefore, it seems difficult to support the clinical decision of recommending 
acupuncture in this patient population. With regard to interventions not included in 
the meta-analysis, there is no evidence, or very weak evidence, that “topical” 
pilocarpine, hyperthermic supersaturated humidification, acupuncture, herbal 
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medicine, ALTENS or LLT can reduce xerostomia symptoms, increase salivary flow, 
or improve QoL in this population.  
Salivary substitutes and mouth care products are widely used in the management of 
xerostomia [12]. We found high heterogeneity among the six studies included in this 
paper and therefore no data pooling was possible. Our systematic review of single 
studies suggests that there is some weak evidence from 2 small studies, of which 
one is at high risk of bias, that enzyme-enriched mouth care products (gel and 
toothpaste) are superior to traditional carboxymethyl-cellulose gel and commercial 
toothpaste at reducing dry mouth symptoms and increase salivation. The effect size, 
where reported, seems to be small (23mm 0-100mm VAS) with unknown clinical 
significance. There is also some weak evidence from one small trial that among 
enzyme-enriched mouth care products, the more viscous one (BioXtra) can lessen 
dry mouth symptoms more than low-viscosity products (Oral Balance); however 
relevant effect size seems small (11·2mm difference on 0-100mmVAS) and clinical 
significance is unknown. With respect to the other three trials on salivary substitutes, 
there remains very weak evidence regarding the beneficial effects of an intra-oral 
device releasing Oral Balance gel, xanthan gum-based salivary substitutes, aloe vera 
gel, rape oil, or mucin spray upon dry mouth symptoms, salivary flow or QoL. 
The present study has a number of limitations. The studies included in this review 
were conducted between 1993 and 2015. During this time the patient population has 
changed, and radiotherapy modalities have also changed, with participants of the 
most recent studies likely receiving lower radiation dosage to salivary glands. Also 
only summary data rather than patient level data were available.  
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Conclusions 
Pilocarpine and cevimeline should represent the first line of therapy in HNC survivors 
with radiotherapy-induced xerostomia and hyposalivation. There is very weak 
evidence that salivary substitutes can provide some, if any, benefit of small 
magnitude and unclear clinical significance. The use of other treatment modalities 
cannot be supported on the basis of current evidence.  
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